FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2768136458> ?p ?o ?g. }

• W2768136458 endingPage "7905" @default.
• W2768136458 startingPage "7899" @default.
• W2768136458 abstract "To prospectively evaluate the efficacy of sofobuvir (SOF) in hepatitis C patients infected with hepatitis C virus (HCV) genotype 3 in Pakistan.The present study was performed with the coordination of gastroenterology and pathology departments of Shalamar Hospital Lahore from August 2014 to May 2016. The total number of patients included in this study was 1375 and all of them were infected with HCV genotype 3. On the basis of drug combinations, all the patients were separated into two groups. The first group of patients was treated for 24 wk with SOF (Sovaldi® by Gilead Sciences) plus ribavirin (RBV) [Ribazol® by Getz Pharma Pakistan (PVT) Ltd], while the patients of the second group were treated with SOF + RBV + pegylated-interferon (pegIFN) alfa-2a (Ropegra by Roach) for 12 wk. HCV genotyping and viral load measurement were performed on fully automated Abbott Real-Time PCR system (Abbott m24sp automated nucleic acid extraction system and Abbott m2000rt amplification system; abbott Molecular, Des Plaines, IL, United States). For the assessment of sustained virological response (SVR), all HCV RNA negative patients were followed for 12 weeks after the treatment completion. Any patient with less than 12 IU/mL viral load after 12 wk of treatment completion was considered as a sustained virological responder (SVR-12).A total of 1375 patients chronically infected with HCV genotype 3 were treated with two drug combinations SOF + RBV and SOF + RBV + pegIFN alfa-2a. On the basis of these drug combinations, patients were divided into two groups (first and second). Overall SVR-12 was excellent in both groups (99.17% and 97.91%). Older patients (> 40 years) of second group showed lower SVR-12 (93.46%) compared to first group older patients (98.79%), while in the younger patients of both groups, the SVR-12 rate was almost the same (99.54% in first group and 99.05% in second group). No such difference regarding SVR-12 rate was seen in males and females of first group patients (99.68% and 98.88%, respectively), while in second group the males were found to be better responders compared to females (98.96% and 95%). The SVR-12 rate in previously treated patients of first group was better (99.34%) than second group (93.70%), while naïve patients of second group were marginally better responders (99.25%) than first group (97.80%). Rapid viral response at week-4 was found to be a very effective predictor for assessing the SVR rate at this stage of therapy in both groups. Headache, anemia and fatigue were common side effects in both groups either treated with SOF + RBV or SOF + RBV + pegIFN alfa-2a, while the overall percentage of the side effects was higher in second group.The remarkable SVR response rate of HCV genotype 3 infected patients to SOF provided a new way to look forward to eliminate hepatitis C from our region." @default.
• W2768136458 created "2017-12-04" @default.
• W2768136458 creator A5003187135 @default.
• W2768136458 creator A5043632647 @default.
• W2768136458 creator A5080600889 @default.
• W2768136458 date "2017-11-28" @default.
• W2768136458 modified "2023-09-25" @default.
• W2768136458 title "Dramatic response of hepatitis C patients chronically infected with hepatitis C virus genotype 3 to sofosbuvir-based therapies in Punjab, Pakistan: A prospective study" @default.
• W2768136458 cites W1502617719 @default.
• W2768136458 cites W1918584766 @default.
• W2768136458 cites W1970160203 @default.
• W2768136458 cites W1987935503 @default.
• W2768136458 cites W1999977881 @default.
• W2768136458 cites W2003104968 @default.
• W2768136458 cites W2004360699 @default.
• W2768136458 cites W2006881280 @default.
• W2768136458 cites W2027545702 @default.
• W2768136458 cites W2032882950 @default.
• W2768136458 cites W2056569478 @default.
• W2768136458 cites W2061466641 @default.
• W2768136458 cites W2065898617 @default.
• W2768136458 cites W2075754452 @default.
• W2768136458 cites W2078251659 @default.
• W2768136458 cites W2087104615 @default.
• W2768136458 cites W2089626753 @default.
• W2768136458 cites W2116047701 @default.
• W2768136458 cites W2125284245 @default.
• W2768136458 cites W2127685726 @default.
• W2768136458 cites W2151338378 @default.
• W2768136458 cites W2160850489 @default.
• W2768136458 cites W2200659981 @default.
• W2768136458 cites W2222306685 @default.
• W2768136458 cites W2317554121 @default.
• W2768136458 cites W2321119966 @default.
• W2768136458 cites W2336799715 @default.
• W2768136458 cites W2419161593 @default.
• W2768136458 cites W2590775171 @default.
• W2768136458 cites W2610483931 @default.
• W2768136458 cites W2740336755 @default.
• W2768136458 cites W3114412741 @default.
• W2768136458 cites W4210961054 @default.
• W2768136458 cites W4211007862 @default.
• W2768136458 doi "https://doi.org/10.3748/wjg.v23.i44.7899" @default.
• W2768136458 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/5703919" @default.
• W2768136458 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/29209131" @default.
• W2768136458 hasPublicationYear "2017" @default.
• W2768136458 type Work @default.
• W2768136458 sameAs 2768136458 @default.
• W2768136458 citedByCount "6" @default.
• W2768136458 countsByYear W27681364582018 @default.
• W2768136458 countsByYear W27681364582019 @default.
• W2768136458 countsByYear W27681364582022 @default.
• W2768136458 countsByYear W27681364582023 @default.
• W2768136458 crossrefType "journal-article" @default.
• W2768136458 hasAuthorship W2768136458A5003187135 @default.
• W2768136458 hasAuthorship W2768136458A5043632647 @default.
• W2768136458 hasAuthorship W2768136458A5080600889 @default.
• W2768136458 hasBestOaLocation W27681364581 @default.
• W2768136458 hasConcept C104317684 @default.
• W2768136458 hasConcept C126322002 @default.
• W2768136458 hasConcept C135763542 @default.
• W2768136458 hasConcept C142462285 @default.
• W2768136458 hasConcept C159047783 @default.
• W2768136458 hasConcept C203014093 @default.
• W2768136458 hasConcept C2522874641 @default.
• W2768136458 hasConcept C2776408679 @default.
• W2768136458 hasConcept C2776455275 @default.
• W2768136458 hasConcept C2776461080 @default.
• W2768136458 hasConcept C2778390639 @default.
• W2768136458 hasConcept C2780040827 @default.
• W2768136458 hasConcept C31467283 @default.
• W2768136458 hasConcept C55493867 @default.
• W2768136458 hasConcept C71924100 @default.
• W2768136458 hasConcept C86803240 @default.
• W2768136458 hasConcept C90924648 @default.
• W2768136458 hasConceptScore W2768136458C104317684 @default.
• W2768136458 hasConceptScore W2768136458C126322002 @default.
• W2768136458 hasConceptScore W2768136458C135763542 @default.
• W2768136458 hasConceptScore W2768136458C142462285 @default.
• W2768136458 hasConceptScore W2768136458C159047783 @default.
• W2768136458 hasConceptScore W2768136458C203014093 @default.
• W2768136458 hasConceptScore W2768136458C2522874641 @default.
• W2768136458 hasConceptScore W2768136458C2776408679 @default.
• W2768136458 hasConceptScore W2768136458C2776455275 @default.
• W2768136458 hasConceptScore W2768136458C2776461080 @default.
• W2768136458 hasConceptScore W2768136458C2778390639 @default.
• W2768136458 hasConceptScore W2768136458C2780040827 @default.
• W2768136458 hasConceptScore W2768136458C31467283 @default.
• W2768136458 hasConceptScore W2768136458C55493867 @default.
• W2768136458 hasConceptScore W2768136458C71924100 @default.
• W2768136458 hasConceptScore W2768136458C86803240 @default.
• W2768136458 hasConceptScore W2768136458C90924648 @default.
• W2768136458 hasIssue "44" @default.
• W2768136458 hasLocation W27681364581 @default.
• W2768136458 hasLocation W27681364582 @default.
• W2768136458 hasLocation W27681364583 @default.
• W2768136458 hasLocation W27681364584 @default.
• W2768136458 hasOpenAccess W2768136458 @default.

• next